Home » Stocks » LTRN

Lantern Pharma, Inc. (LTRN)

Stock Price: $14.34 USD -0.17 (-1.17%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 90.47M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.22M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $14.34
Previous Close $14.51
Change ($) -0.17
Change (%) -1.17%
Day's Open 14.40
Day's Range 13.77 - 14.75
Day's Volume 2,038,566
52-Week Range 10.70 - 21.25

News

Hide News
PRNewsWire - 1 day ago

DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADRĀ® artificial intelligence ("A.I.") platform to transform cance...

PRNewsWire - 1 week ago

DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADRĀ® artificial intelligence ("A.I.") platfor...

About LTRN

Lantern Pharma, a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent... [Read more...]

Industry
Biotechnology
IPO Date
Jun 11, 2020
CEO
Panna Sharma
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
LTRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Lantern Pharma stock is "Buy." The 12-month stock price forecast is 27.33, which is an increase of 90.59% from the latest price.

Price Target
$27.33
(90.59% upside)
Analyst Consensus: Buy